BBOT

BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT

Overview Fund Activity

31 hedge funds and large institutions have $167M invested in BridgeBio Oncology Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACP
1
Acuta Capital Partners
California
$1.82M
2
TD Asset Management
2
TD Asset Management
Ontario, Canada
$1.48M
3
Millennium Management
3
Millennium Management
New York
$11.4M
4
Walleye Capital
4
Walleye Capital
New York
$949K
5
ACM
5
ADAR1 Capital Management
Texas
$4.13M

Top Sellers

1
Wellington Management Group
1
Wellington Management Group
Massachusetts
$1.89M
2
CAC
2
Cowen and Company
New York
$516K
3
WP
3
Woodline Partners
California
$1.06M
Name Holding Trade Value Shares
Change 		Shares
Change %
MCM
26
Moore Capital Management
New York
$1.02M – – –
Walleye Capital
27
Walleye Capital
New York
$949K +$6.54K +640 +0.7%
Walleye Trading
28
Walleye Trading
New York
$534K +$3.68K +360 +0.7%
CAC
29
Cowen and Company
New York
$516K -$39.9K -3,902 -7%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$111K – – –
JPMorgan Chase & Co
31
JPMorgan Chase & Co
New York
$41 – – –
1
2